Screener
Apogee Therapeutics, Inc. APGE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Other income, net: | ||
| Interest income, net | 8,740 | 7,840 |
| Total other income, net | 8,740 | 7,840 |
| Net loss before taxes | (74,032) | (55,256) |
| Provision for income taxes | (79) | (83) |
| Net loss after taxes | $(74,111) | $(55,339) |
| Net loss per share, basic and diluted | $(1.06) | $(0.95) |
| Weighted-average common shares outstanding, basic and diluted | 69,668,439 | 58,195,272 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s EPS (diluted)?
- Apogee Therapeutics, Inc. (APGE) reported EPS (diluted) of -$1.06 in Q1 2026.
- How has Apogee Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Apogee Therapeutics, Inc.'s EPS (diluted) decreased by 11.6% year-over-year, from -$0.95 to -$1.06.
- What is the long-term trend for Apogee Therapeutics, Inc.'s EPS (diluted)?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s EPS (diluted) has grown at a -23.0% compound annual growth rate (CAGR), from -$7.12 to -$4.22.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Apogee Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude